🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524375-23-00
Authorised Phase I

OV-PRIME-R (Oncolytic Virotherapy to enhance PReoperative IMmunotherapy Efficacy in patients with proficient mismatch repair (pMMR) Rectal cancer

2025-524375-23-00 · tracked via the Priya Life Science EU tracker
Sponsor
Region Hovedstaden
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Neoplasms
Decision date
23/02/2026
Enrollment target
20
Sites
Denmark

Condition studied

Rectal cancer with proficient mismatch repair (pMMR)

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524375-23-00 on CTIS ↗ ← All trials in the EU